EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effects of High Amylose-Resistant Starch on Gut Microbiota and Uremic Toxin Levels in Patients With Stage-G3a-G4 Chronic Kidney Disease: A Randomized Trial

Samuel A Headley, Donna J Chapman, Michael J Germain, Elizabeth E Evans, Karen L Madsen, Emily M Miele, Kristyn Kirton, Joshua Loseke, Allen Cornelius, Brian Martin, Bradley Nindl, Heekuk Park und 2 weitere

Journal of Renal Nutrition · 2025

DOI: 10.1053/j.jrn.2024.09.005 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Renal Nutrition, 2025. Verfasst von Samuel A Headley und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Exercise Science, Springfield College, Springfield, Massachusetts. Electronic address: sheadley@springfieldcollege.edu. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Renal Insufficiency, Chronic, Uremic Toxins, Amylose. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study was designed to determine the effect of 16 weeks of supplementation with Hi-maize 260 resistant starch (RS) on the gut microbiota, uremic toxins (indoxyl sulfate and p-cresyl sulfate [PCS]), markers of inflammation, and oxidative stress along with vascular function in patients with stage G3a-G4 chronic kidney disease (CKD). DESIGN AND METHODS: This was a double-blind, placebo-controlled, parallel-arm, randomized controlled trial. Sixty-eight patients with stage-G3a-G4 CKD were randomized to either RS with usual care or placebo and usual care. Patients attended four testing sessions as follows: two baseline (BL) visits and follow-up visits at 8 and 16 weeks. Fasting blood samples, resting brachial and central blood pressures, along with arterial stiffness, were collected at visits (1 or 2) and weeks 8 and 16. A stool sample was collected for analysis of microbial composition at BL and week 16. Patients were randomized after the BL visits. RESULTS: Patients receiving the RS had a reduction in PCS at week 16. This reduction was associated with a decrease in microbial α-diversity between BL and week 16 (Chao1 P = .014, Shannon P = .017, phylogenetic diversity P = .046, and Simpson P = .017) as well as increases in Subdoligranulum (P = .03) and Oscillospiraceae Unclassified Clostridiales Group 002 (P = .02) and decreases in Bacteroides (P = .009).There were no changes in microbial beta diversity and other biomarkers or markers of vascular function following the 16-week period. CONCLUSION: Sixteen weeks of supplementation of RS in patients with stage-G3a-G4 CKD led to changes in microbial composition that were associated with a significant reduction in PCS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeRenal Insufficiency, ChronicUremic ToxinsAmyloseResistant StarchStarchHumansFemaleMaleMiddle AgedDouble-Blind MethodCresolsAgedIndicanSulfuric Acid EstersDietary SupplementsBiomarkersFecesOxidative StressAdult

Stichwörter der Autor:innen

inflammationmicrobiomepredialysisresistant starch

Substanzen

Uremic ToxinsCresolsAmylose4-cresol sulfateIndicanSulfuric Acid EstersResistant StarchBiomarkersStarch

Autor:innen und Institutionen

  • Department of Exercise Science, Springfield College, Springfield, Massachusetts. Electronic address: sheadley@springfieldcollege.edu.
  • Department of Exercise Science, Springfield College, Springfield, Massachusetts.
  • Renal and Transplant Associates of New England, Springfield, Massachusetts.
  • Department of Gastroenterology, University of Alberta, Edmonton, Canada.
  • School of Psychology, Fielding Graduate University, Colorado Springs, Colorado.
  • Neuromuscular Research Laboratory/Warrior Human Performance Research Center, Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania.

Zitieren

APA

Headley, S. A., Chapman, D. J., Germain, M. J., Evans, E. E., Madsen, K. L., Miele, E. M., Kirton, K., Loseke, J., Cornelius, A., Martin, B., Nindl, B., Park, H., Vaziri, N. D., & Ikizler, T. A. (2025). Effects of High Amylose-Resistant Starch on Gut Microbiota and Uremic Toxin Levels in Patients With Stage-G3a-G4 Chronic Kidney Disease: A Randomized Trial. Journal of Renal Nutrition. https://doi.org/10.1053/j.jrn.2024.09.005

Vancouver

Headley SA, Chapman DJ, Germain MJ, Evans EE, Madsen KL, Miele EM, et al. Effects of High Amylose-Resistant Starch on Gut Microbiota and Uremic Toxin Levels in Patients With Stage-G3a-G4 Chronic Kidney Disease: A Randomized Trial. Journal of Renal Nutrition. 2025. doi:10.1053/j.jrn.2024.09.005

BibTeX
@article{Headley2025,
  author = {Headley, Samuel A and Chapman, Donna J and Germain, Michael J and Evans, Elizabeth E and Madsen, Karen L and Miele, Emily M and Kirton, Kristyn and Loseke, Joshua and Cornelius, Allen and Martin, Brian and Nindl, Bradley and Park, Heekuk and Vaziri, Nosratola D and Ikizler, Talat Alp},
  title = {Effects of High Amylose-Resistant Starch on Gut Microbiota and Uremic Toxin Levels in Patients With Stage-G3a-G4 Chronic Kidney Disease: A Randomized Trial},
  journal = {Journal of Renal Nutrition},
  year = {2025},
  doi = {10.1053/j.jrn.2024.09.005}
}
Kostenlos starten →